Currently, patients with CRC are not recommended to receive anti‐EGFR therapy if they have mutations in RAS (KRAS, HRAS or NRAS), or BRAF, the exception being when given in combination with drugs (vemurafenib) targeting the BRAF‐V600E mutation, in combination with irinotecan and cetuximab [52]. Here, KRAS is linked to colorectal carcinoma.